Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2
暂无分享,去创建一个
Jianping Ding | Hongzhou Lu | Lu Lu | R. Yan | S. Yuan | Jianqing Xu | Longfei Ding | Chen Zhao | Xiaoyan Zhang | S. Xia | Yaguang Zhang | Xiuling Li | Youhua Xie | Xingchen Chen | Tianlong Zhang | Q. Deng | Chenli Qiu | Gaowei Hu | Shuangfeng Chen | Gary Wong | Liyan Ma | Z. Ling | Xiaoyu Sun | Chenjian Gu | Xu Zhou | Xiao Lu | Zhuo Yang | Bing Sun | Shujuan Du | Yuanfei Zhu | C. Yi | Wangpeng Gu | Xin-chun Chen | Mu Liu | Yadong Fu | Weihui Fu | Yong-huai He | Ai-dong Qu | Qiang Zhou | C. Qiu | Shuai Xia | Xiaoyu Sun
[1] Jianping Ding,et al. Unique binding pattern for a lineage of human antibodies with broad reactivity against influenza A virus , 2022, Nature Communications.
[2] D. Burton,et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection , 2022, Science Translational Medicine.
[3] D. Burton,et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection , 2022, bioRxiv.
[4] Liyuan Liu,et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.
[5] M. Beltramello,et al. Broad betacoronavirus neutralization by a stem helix–specific human antibody , 2021, Science.
[6] G. Pantaleo,et al. A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma , 2021, Science Translational Medicine.
[7] J. Taubenberger,et al. Increasing threats from SARS-CoV-2 variants: Time to establish global surveillance , 2021, Science Translational Medicine.
[8] A. Walls,et al. Structural basis for broad coronavirus neutralization , 2021, Nature Structural & Molecular Biology.
[9] B. Haynes,et al. Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions , 2021, Cell Reports Medicine.
[10] F. Grosveld,et al. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies , 2021, Nature Communications.
[11] N. Sullivan,et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine - Preliminary Report. , 2021, The New England journal of medicine.
[12] P. Dormitzer,et al. Neutralizing Activity of BNT162b2-Elicited Serum - Preliminary Report. , 2021, The New England journal of medicine.
[13] E. Hodcroft,et al. Public health actions to control new SARS-CoV-2 variants , 2021, Cell.
[14] Lisa E. Gralinski,et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody , 2021, Science.
[15] Lei Liu,et al. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry , 2021, Nature communications.
[16] Peter B Rosenthal,et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion , 2020, Nature.
[17] S. Rawson,et al. Distinct conformational states of SARS-CoV-2 spike protein , 2020, Science.
[18] M. Nussenzweig,et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies , 2020, Cell.
[19] Z. Rao,et al. Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic antibody , 2020, Science.
[20] William J. Liu,et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.
[21] X. Xie,et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.
[22] Jianqing Xu,et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies , 2020, Cellular & Molecular Immunology.
[23] F. Gao,et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.
[24] Y. Malik,et al. Properties of Coronavirus and SARS-CoV-2. , 2020, The Malaysian journal of pathology.
[25] Rongguang Zhang,et al. Junctional and somatic hypermutation-induced CX4C motif is critical for the recognition of a highly conserved epitope on HCV E2 by a human broadly neutralizing antibody , 2020, Cellular & Molecular Immunology.
[26] Zhènglì Shí,et al. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion , 2020, Cell Research.
[27] Yuxian He,et al. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity , 2020, Journal of Virology.
[28] James M. Hyman,et al. New coronavirus outbreak: Framing questions for pandemic prevention , 2020, Science Translational Medicine.
[29] Young-Jun Park,et al. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.
[30] Kai Zhao,et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.
[31] Lu Lu,et al. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike , 2019, Science Advances.
[32] Zhènglì Shí,et al. Origin and evolution of pathogenic coronaviruses , 2018, Nature Reviews Microbiology.
[33] S. Hoffman,et al. A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein , 2018, Nature Medicine.
[34] A. Walls,et al. Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion , 2017, Proceedings of the National Academy of Sciences.
[35] Jianping Ding,et al. Human antibody 3E1 targets the HA stem region of H1N1 and H5N6 influenza A viruses , 2016, Nature Communications.
[36] P. Zhou,et al. Epitope-focused vaccine design against influenza A and B viruses. , 2016, Current opinion in immunology.
[37] P. Collins,et al. Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes , 2016, Cell.
[38] K. Yuen,et al. Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein , 2014, Science Translational Medicine.
[39] Xavier Robert,et al. Deciphering key features in protein structures with the new ENDscript server , 2014, Nucleic Acids Res..
[40] David Baker,et al. Proof of principle for epitope-focused vaccine design , 2014, Nature.
[41] A. Osterhaus,et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.
[42] Baoshan Zhang,et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.
[43] Charles M. Rice,et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus , 2012, Proceedings of the National Academy of Sciences.
[44] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[45] Martin H. Koldijk,et al. A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.
[46] S. McNicholas,et al. Presenting your structures: the CCP4mg molecular-graphics software , 2011, Acta crystallographica. Section D, Biological crystallography.
[47] Randy J. Read,et al. Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.
[48] P. Talbot,et al. Vacuolating encephalitis in mice infected by human coronavirus OC43 , 2003, Virology.
[49] Christian Drosten,et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[50] J. A. Comer,et al. A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.
[51] D. Burton,et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge , 2008, Nature Medicine.
[52] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[53] W. Delano. The PyMOL Molecular Graphics System , 2002 .
[54] Vincent B. Chen,et al. Acta Crystallographica Section D Biological , 2001 .
[55] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.